Qatar MOPH Pharmaceutical Import: A Complete 2026 Guide for UK Exporters

Qatar is one of the most pharmaceutically interesting markets in the Gulf. The country has a small resident population of approximately three million, the highest GDP per capita in the world, and a healthcare system that is roughly 97 per cent dependent on imported pharmaceutical supply. Hospital procurement is concentrated through a small number of very large institutional buyers, principally Hamad Medical Corporation, which between them set the pharmaceutical formulary for the bulk of the population. For UK pharmaceutical exporters operating under MHRA Wholesale Dealer Authorisation, Qatar represents a high-value, regulator-friendly, logistically excellent destination for specialty oncology, rare disease, biologic, paediatric, named patient and shortage supply.

The regulator that controls every aspect of pharmaceutical import into Qatar is the Ministry of Public Health, the MOPH, working through its Pharmacy and Drug Control Department. The 2022 FIFA World Cup left a substantial legacy of upgraded pharmaceutical handling infrastructure at Hamad International Airport, expanded mass-casualty preparedness frameworks across HMC, and a level of operational maturity in international pharmaceutical logistics that exceeds the regional average. The National Health Strategy 2024 to 2030 has set clear priority directions across non-communicable diseases, mental health, the ageing population, paediatrics and cancer care, all of which translate into specific procurement opportunities for UK exporters.

This guide covers the full process for UK exporters in 2026: market context, MOPH structure, the principal routes to market, documentation, registration timelines, HMC procurement, Sidra Medicine, the private hospital sector, the National Health Strategy 2024 to 2030 priority areas, Doha cold chain considerations, the FIFA World Cup logistics legacy, named patient pathway specifics, common pitfalls, and how Euro Biom supports UK to Qatar pharmaceutical supply. It complements our adjacent Saudi Arabia and UAE import guide and our Qatar pharmaceutical exporter landing page.

Qatar Pharma Market Context in 2026

Qatar's pharmaceutical market is small in absolute terms compared with Saudi Arabia, the UAE or Egypt, but it is one of the highest per-capita pharmaceutical spending markets in the world. The country has effectively no domestic pharmaceutical manufacturing of significance, relying on imports for an estimated 97 per cent of finished pharmaceutical demand. The market is dominated by branded originator products, with a steadily growing biosimilar and high-quality generic share consistent with MOPH's value-based procurement reforms.

Three structural features make Qatar particularly important for UK exporters. First, healthcare expenditure is heavily public and is rising. Second, hospital procurement is highly concentrated, principally through Hamad Medical Corporation, which makes commercial conversations with the right institutional buyer disproportionately impactful. Third, the regulatory environment is transparent, GCC-aligned and increasingly digitised, lowering the operational friction of doing business compared with several other markets in the region.

Qatar's National Health Strategy 2024 to 2030 has identified five priority directions that shape the pharmaceutical demand profile for the rest of the decade. These are non-communicable disease management, mental health and behavioural health expansion, healthy ageing and the dignified-life pathway for the elderly population, women and child health with a strong paediatrics emphasis driven by Sidra Medicine, and cancer care anchored by the National Center for Cancer Care and Research at HMC. UK exporters with credible products in any of these five priority directions have a structurally favourable environment in which to position UK to Qatar supply.

MOPH Structure: Pharmacy and Drug Control Department

The Qatar Ministry of Public Health is the apex national regulator, responsible for the country's healthcare policy framework, the licensing of healthcare professionals and facilities, and the regulation of medicines, medical devices, controlled drugs and pharmacy practice. The operational unit responsible for pharmaceutical regulation is the Pharmacy and Drug Control Department, sometimes referenced in MOPH documentation as the Department of Pharmacy and Drug Control or simply Drug Control Department.

The Pharmacy and Drug Control Department within MOPH is structured around several functional teams that any UK exporter or its Qatari local agent will encounter during the import process:

• Drug Registration, handling new and renewal marketing authorisation applications for finished products, biologicals and vaccines
• Drug Inspection and GMP, conducting GMP recognition and inspection arrangements for foreign manufacturing sites
• Import and Export Licensing, issuing the shipment-specific import permits that customs requires for clearance, and managing controlled drugs licensing
• Pharmacy Practice, licensing pharmacists, pharmacies and pharmaceutical companies operating in Qatar
• Pharmacovigilance, the national focal point for safety reporting and signal detection
• Special Use Committee, reviewing applications for unregistered medicines required for specific identified patients
• Pricing, setting the registered retail price within the Qatar pricing framework

Qatar is also a participating member of the Gulf Cooperation Council pharmaceutical harmonisation framework, which allows for the GCC central registration of pharmaceuticals through the Saudi Food and Drug Authority's executive office, with downstream recognition pathways in MOPH. UK exporters with products that have undertaken GCC central registration can use that pathway to accelerate Qatar-specific registration, although MOPH retains the right to require national-level supplementary review.

Routes to the Qatari Market

There are four practical routes for a UK pharmaceutical product to reach a patient in Qatar. Each has its own documentation, timelines and commercial structure, and each suits a different class of product.

Route 1: Full MOPH registration

This is the standard pathway for products intended for routine commercial supply. A UK manufacturer or marketing authorisation holder appoints a Qatar-licensed local agent, which is the legal entity that holds the marketing authorisation and submits all dossiers, variations and pharmacovigilance reports on behalf of the foreign manufacturer. The dossier is filed in GCC-harmonised CTD format. Once the marketing authorisation is granted and the price is approved, the product can be imported through repeat shipment-specific import permits, distributed across Qatar, and tendered into HMC, Sidra and the private sector. MOPH registration is the only route that supports volume supply.

Route 2: Named patient through the Special Use Committee

For products that are not registered with MOPH but are clinically required for a specific identified Qatari patient, the Special Use Committee operates Qatar's named patient and unregistered import pathway. A treating physician confirms in writing that no licensed alternative is available locally, the hospital's pharmacy and therapeutics committee endorses the request, and a licensed local agent files the application with MOPH. The supplier documentation, particularly the Certificate of Pharmaceutical Product issued by the MHRA, the manufacturer's GMP certificate and the batch documentation, is required as part of the application. This is the principal route for a UK MHRA-licensed wholesaler supporting Qatari oncology, rare disease, paediatric and advanced therapy supply, and it sits closely alongside our broader named patient supply service.

Route 3: HMC and Sidra direct procurement

Hamad Medical Corporation and Sidra Medicine are licensed to procure pharmaceuticals directly from approved international suppliers, including UK MHRA-licensed wholesalers, where the product is registered with MOPH or holds a Special Use authorisation. HMC's supply chain management division and Sidra's central pharmacy run periodic tenders and standing orders for active formulary products, and operate ad hoc emergency procurement for urgent shortage cover. Direct supply into HMC and Sidra is structurally faster than the layered importer model used in some neighbouring markets, and is one of the reasons Qatar is operationally attractive for UK exporters with the right product portfolio. This sits alongside our broader tender and government supply work.

Route 4: Licensed local agent supply to private hospitals

The private hospital sector in Qatar, including Aspetar, Al Ahli Hospital, Doha Clinic and several specialist clinics in West Bay and The Pearl, procures pharmaceuticals through Qatar-licensed importers who hold the relevant MOPH import permits. UK exporters supplying this segment work through the local agent of the marketing authorisation holder, with the agent managing import permit application, customs clearance and onward distribution to the receiving hospital pharmacy.

Documentation Required for a Qatar Shipment

The Qatar Pharmacy and Drug Control Department and Qatari customs expect a precise documentation package for every pharmaceutical import. Documentation gaps are the leading cause of clearance delays at Hamad International Airport. A UK MHRA-licensed wholesale dealer should be in a position to issue or compile the following on every shipment.

Bilingual labelling, Arabic and English, is the Qatar default. The MOPH expects the outer carton, the patient information leaflet and, for many product categories, the primary container to carry compliant Arabic and English text covering the product name, the active ingredient, the strength, the dosage form, the storage instructions, the expiry date, and the importer details. For named patient shipments, the local agent's labelling partner usually applies the bilingual over-label after customs release under MOPH-approved supervision.

MOPH Registration Timeline and Process

Registering a UK-manufactured pharmaceutical product with the Qatar Ministry of Public Health is a structured process aligned with the GCC harmonised technical document framework. The process can be broken into the following stages, which together typically span 9 to 18 months for a new molecule and 18 to 24 months for a biological or complex generic.

1. Local representation, appointment of a Qatar-licensed local agent who will file the dossier and hold the marketing authorisation
2. Pre-submission alignment, increasingly used for complex products, allowing MOPH to flag dossier expectations and any likely deficiencies in advance
3. Dossier preparation, compilation of the GCC-harmonised CTD with Qatar-specific addenda, including the CPP, GMP certificate, bilingual labelling text, Qatar-format product information and halal evidence where applicable
4. Pricing application, submitted in parallel, comparing the proposed Qatar price to the comparator basket, evidencing the manufacturing currency
5. Technical review, MOPH reviewers assess the chemistry, manufacturing and controls section, the non-clinical and clinical sections, and the local addenda
6. GMP recognition, physical or desk inspection of the UK manufacturing site, recognition of MHRA equivalence is well-established
7. Pricing approval, once technical review is positive, the pricing decision is issued
8. Marketing authorisation, MOPH issues the registration certificate and adds the product to the Qatar register
9. Initial import, the local agent files the first shipment-specific import permit application against the new registration

Fast-track pathways are available for orphan medicines, oncology innovations, paediatric-only formulations and products designated as priority by MOPH. Qatar's regulatory practice has been to compress timelines significantly for products with a clear public health rationale, particularly where a product has already secured EMA, MHRA or FDA approval and where the CPP is robust. A GCC central registration secured through the SFDA-administered route is recognised under MOPH's downstream pathway, although Qatar retains the right to require national-level supplementary review.

Hamad Medical Corporation: Qatar's Dominant Hospital Buyer

Hamad Medical Corporation is by far the largest pharmaceutical buyer in Qatar and one of the largest single-system hospital buyers in the GCC. HMC operates a network of speciality and general hospitals across the country, all using a common pharmaceutical formulary managed centrally and a common procurement function under HMC supply chain management. Understanding how HMC procures, formulary decisions are taken and tenders are run, is essential commercial knowledge for any UK exporter targeting Qatar.

The principal HMC facilities for pharmaceutical procurement are:

• Hamad General Hospital, Doha, Qatar's flagship tertiary hospital, principal trauma and complex care centre
• Women's Wellness and Research Center, Doha, the tertiary maternity, gynaecology and reproductive medicine centre
• Al Wakra Hospital, the regional general hospital serving the southern population
• Al Khor Hospital, the regional general hospital serving the northern population
• The Cuban Hospital, Dukhan, serving the western industrial corridor
• Mental Health Hospital, the dedicated psychiatric and addiction services centre
• National Center for Cancer Care and Research, NCCCR, Qatar's principal oncology and haematology centre
• Communicable Disease Center, Qatar's infectious diseases referral centre
• Heart Hospital, tertiary cardiac and cardiothoracic care
• Rumailah Hospital, rehabilitation, geriatrics and dental services

HMC procurement runs through a combination of central tenders, framework agreements and ad hoc emergency procurement. Active formulary products are typically tendered annually or biennially, with named patient and Special Use products procured on an as-needed basis through the central pharmacy. NCCCR is a particularly active buyer for UK oncology supply, with a strong appetite for UK-sourced specialty oncology, supportive care and rare-tumour therapy.

Sidra Medicine: Paediatric and Women's Specialty Procurement

Sidra Medicine, the dedicated paediatric and women's specialty hospital located in Qatar Foundation's Education City, runs its procurement track separately from HMC. Sidra is a tertiary and quaternary specialty centre with strong programmes in paediatric oncology, neonatal intensive care, paediatric surgery, women's health, fertility care, genetic medicine and clinical research.

Sidra's pharmaceutical procurement profile is distinctive: a high proportion of paediatric-specific formulations, neonatal products, rare disease therapies, advanced therapy medicinal products including gene therapies, and a meaningful unregistered medicine import volume reflecting the rarity and specificity of the patient population. UK exporters with credible paediatric and rare disease product portfolios have a structurally favourable environment at Sidra, particularly through the Special Use pathway, where Sidra's pharmacy and therapeutics committee operates with substantial clinical depth.

Private Hospital Sector and Specialty Centres

Beyond HMC and Sidra, Qatar has a meaningful private hospital and specialty centre sector serving the country's expatriate workforce, the resident population covered by private health insurance, and a substantial medical tourism inflow particularly from neighbouring GCC countries. The principal private hospitals and specialty centres are:

• Aspetar, Doha, the world-leading sports medicine and orthopaedic specialty centre, an active buyer of niche orthopaedic, regenerative medicine and sports pharmacology products
• Al Ahli Hospital, a major multi-specialty private hospital in Doha
• Doha Clinic Hospital, a private multi-specialty centre
• Ahmed bin Mohammed Military Hospital, the medical service for the Qatar Armed Forces
• Naufar, a wellness and behavioural health centre
• Al Khor Welfare Hospital and several smaller private clinics

Private hospital procurement runs through Qatar-licensed importers who hold the relevant MOPH import permits. Insurance reimbursement under Qatar's national insurance framework is a meaningful determinant of which products gain traction, and UK exporters working through licensed local agents should have visibility on the insurance positive list status of the products they are introducing.

National Health Strategy 2024 to 2030

Qatar's National Health Strategy 2024 to 2030 is the framework that shapes pharmaceutical demand for the rest of the decade. The strategy identifies five priority directions, each with measurable targets and dedicated implementation plans within MOPH and HMC. UK exporters should position their portfolios against these priorities at the dossier stage and in their Qatar commercial planning.

Non-communicable diseases

Cardiovascular disease, diabetes, chronic respiratory disease and cancer together account for the majority of mortality and morbidity in Qatar. The strategy places strong emphasis on improving long-term outcomes through preventive medicine, early diagnosis and chronic disease management. Pharmaceutical demand profile: cardiology, diabetes, respiratory, oncology and supportive care, with a clear preference for evidence-rich products that demonstrate long-term outcome benefit.

Mental health and behavioural health

Mental Health Hospital expansion and outpatient mental health service rollout across primary care has been a national priority since the National Mental Health Strategy launch. Pharmaceutical demand profile: psychiatry, including atypical antipsychotics, antidepressants, ADHD therapies, addiction medicine and increasingly digital therapeutics adjuncts.

Healthy ageing and dignified-life pathway

Qatar's resident population is ageing, particularly the Qatari national population, and the strategy includes a dignified-life pathway focused on geriatric medicine, age-appropriate pharmacotherapy, dementia care, falls prevention, polypharmacy management and end-of-life care. Pharmaceutical demand profile: geriatrics, neurology, palliative care, ophthalmology and orthopaedics.

Women and child health

Anchored by Sidra Medicine, this priority covers neonatal and paediatric care, women's reproductive health, fertility care and adolescent health. Pharmaceutical demand profile: paediatric formulations, neonatal therapies, paediatric oncology, paediatric rare disease, obstetrics and women's health.

Cancer care

The National Center for Cancer Care and Research at HMC is the centrepiece of Qatar's cancer strategy, covering screening, diagnosis, multidisciplinary treatment and palliative care. Pharmaceutical demand profile: solid tumour and haematological oncology, immunotherapy, targeted therapy, supportive care, paediatric oncology in collaboration with Sidra, and named patient access for novel oncology products awaiting routine registration.

Doha Cold Chain: Heathrow to DOH at 47 Degrees Celsius

Qatari summer ambient temperatures regularly exceed 45 degrees Celsius, with sustained periods above 47 degrees Celsius across June, July and August. Pharmaceutical cold chain integrity from London Heathrow through to a Doha hospital pharmacy requires careful design, particularly during summer months and during the Hajj-period freight peak where airline cargo capacity is constrained.

For 2 to 8 degrees Celsius products, the standard model is qualified passive packaging or active container shipping, with full data logger coverage from the UK warehouse through to delivery acceptance. Hamad International Airport's pharmaceutical handling lane was substantially upgraded ahead of the FIFA World Cup and operates to a high standard, with dedicated temperature-controlled storage, GDP-trained ground handling and a properly-conditioned dwell area. The principal cold chain risk on the Heathrow to Doha lane is the road segment from Hamad International to the receiving hospital, which during midsummer can expose product to ambient excursion if the vehicle is not properly pre-cooled. We recommend agreed ambient excursion limits, pre-cooled vehicles and a contingency plan for shipment hold at the airport temperature-controlled storage if onward transport conditions are not safe. The framework is set out in detail in our cold chain pharmaceutical supply guide.

For frozen biologics and advanced therapies, dry ice replenishment and qualified maintenance time must be agreed contractually with the local agent, and the UK supplier must specify the worst-case transit time the packaging is qualified for. We typically advise Qatari partners to plan for at least 96 hours of qualified maintenance for any 2 to 8 degrees Celsius shipment routed through Doha, and at least 72 hours of qualified maintenance for frozen shipments, allowing margin for customs delay and onward distribution.

FIFA World Cup 2022 Legacy on Pharmaceutical Logistics

The 2022 FIFA World Cup left a substantial and durable legacy on Qatar's pharmaceutical and emergency medical infrastructure. The investment programme delivered upgraded mass-casualty preparedness frameworks across HMC, expanded ambulance and pre-hospital emergency medicine capability, accelerated digital health initiatives at HMC including unified electronic prescribing, modernised pharmaceutical handling capacity at Hamad International Airport including expanded temperature-controlled cargo capacity, and put in place command-and-control structures for high-volume international medical logistics.

The day-to-day legacy effect for UK to Qatar pharmaceutical supply in 2026 is faster pharmaceutical handling at Doha airport, a more sophisticated cold chain logistics ecosystem with multiple GDP-trained ground handlers, an institutional confidence in handling complex international supply, and a clearer command-and-control framework for emergency procurement. Qatar emerged from the World Cup with operational pharmaceutical logistics capabilities that exceed those of several substantially larger markets in the region.

For a UK exporter, the practical implication is that Doha is one of the easiest GCC capitals to ship into operationally, with pharmaceutical-trained ground handling, predictable customs processing and a healthcare ecosystem accustomed to handling international supply at scale.

Named Patient Pathway Specifics in Qatar

Qatar's named patient pathway, formally the Special Use authorisation, is the principal route for UK MHRA-licensed wholesalers supplying unregistered medicines to specific Qatari patients. The pathway operates through MOPH's Special Use Committee, with the institutional layer determined by where the patient is being treated.

For HMC patients, the typical sequence is: treating physician documents the clinical justification and confirms no licensed alternative is available locally, the HMC central pharmacy reviews the request, the HMC pharmacy and therapeutics committee endorses the request at its next scheduled meeting, the request is forwarded to MOPH with the full supplier documentation, and the MOPH Special Use Committee issues the authorisation. The end-to-end timeline can run from a few days for genuinely urgent oncology, paediatric or rare disease cases, through to several weeks for less urgent cases or where documentation requires iteration.

For Sidra Medicine patients, the pathway is similar with Sidra's own pharmacy and therapeutics committee in place of HMC's. Sidra's clinical depth in paediatrics and rare disease typically results in a more medically-detailed request package, which is helpful at the MOPH Special Use Committee stage.

For private hospital patients, the request is initiated by the treating physician, endorsed by the institution's pharmacy committee, and routed through the licensed local agent to MOPH. The supplier documentation expectations are identical, and the UK MHRA-licensed wholesaler's role is the same.

UK suppliers should not commit to a delivery date before the Special Use authorisation is in hand, and Qatari partners should be encouraged to file these applications early and with supporting clinical documentation already pre-aligned with MOPH expectations.

Common Pitfalls in UK to Qatar Supply

Across the UK to Qatar pharmaceutical supply lane, the same operational issues recur often enough to deserve specific attention.

Label language compliance

Qatar's bilingual Arabic and English labelling expectations are precise. Translation errors, missing fields, incorrect importer details, or English-only labelling without Arabic, are common reasons for customs hold. UK suppliers should insist on a labelling proof from the local agent before shipping any new product code, and should retain a controlled copy of each approved label revision in their documentation file.

Halal certification ambiguity

For products containing gelatin, certain biologicals or specific excipient profiles, halal certification expectations vary by product category. UK exporters should confirm with the local agent at the dossier stage whether halal evidence is required, and from which certification body. Qatar generally accepts the major regional halal certification authorities, but should not be assumed.

Ethics committee timelines

For named patient supply into HMC and Sidra Medicine, the institution's pharmacy and therapeutics committee timeline must be planned for in addition to the MOPH Special Use timeline. These committees often meet weekly or biweekly, and the right sequencing of clinician request, hospital approval, MOPH approval and supplier dispatch is the difference between a two-week supply and a four-week supply for the same patient.

Local agent capacity

The Qatar local agent landscape is concentrated, with a small number of well-established licensed agents handling the majority of pharmaceutical imports. A capable local agent is the single biggest determinant of operational success on the UK to Qatar lane. UK exporters should evaluate prospective local agents on their MOPH track record, their HMC and Sidra relationships, their cold chain capability and their response times before committing to a long-term arrangement.

FX and pricing tension

Qatar operates a stable USD-pegged Riyal, which removes a significant share of the FX risk seen in some neighbouring markets. However pricing tension at MOPH registration, particularly for high-cost specialty products, remains a reality. UK exporters should agree pricing positions, indexation language and tendering parameters contractually with the local agent before the dossier is filed.

Shipment-specific import permit timing

MOPH issues a shipment-specific import permit for each consignment. The local agent files the permit application and the lead time can range from 24 to 72 hours for a fully documented routine product. For Special Use shipments, the permit is issued in parallel with the Special Use authorisation. Filing late, or filing without the full supplier documentation, is a frequent cause of last-mile delay. UK suppliers and local agents should align on a per-shipment checklist that triggers the permit application as soon as the shipment is stocked at Heathrow, not when it dispatches.

How Euro Biom Supports UK to Qatar Supply

Euro Biom is an MHRA-licensed UK pharmaceutical wholesale dealer, holding WDA(H) 59239, with our principal warehouse at Heathrow. We support UK to Qatar pharmaceutical supply across three core service lines, alongside our broader service portfolio and the wider GCC region landing page.

For named patient and unregistered medicine supply, we work directly with Qatar-licensed local agents, HMC central pharmacy and Sidra Medicine to assemble the supplier-side documentation package the MOPH Special Use Committee expects. This typically includes the MHRA-issued Certificate of Pharmaceutical Product in WHO format, the manufacturer's GMP certificate, the batch-specific Certificate of Analysis, the manufacturer's batch release, the GDP chain-of-custody record, full temperature data and the legalised commercial documentation. Our clinical desk supports the local agent through the Special Use application where supplier evidence is required.

For shortage and emergency supply, our Heathrow stockholding and our network of UK GMP manufacturers allow us to dispatch within 24 to 72 hours of confirmed enquiry for products held in active stock, with delivery into Doha within 24 to 48 hours of dispatch. Heathrow to Hamad International Airport is one of the easiest pharmaceutical lanes in the world operationally, and we structure our team to respond same day to Qatari-initiated enquiries during Doha working hours.

For institutional and tender supply, we work with Qatar-licensed local agents participating in HMC, Sidra Medicine and MOPH-aligned tenders, providing product availability confirmation, full pricing, full documentation and delivery commitments suitable for tender submissions. This sits alongside our experience supporting UK to Saudi Arabia and UAE pharmaceutical import and other GCC supply lanes.

Our published guidance for HMC, Sidra Medicine and Qatar-licensed local agents is that the most reliable UK to Qatar supply lane is built on three principles: a UK supplier with current MHRA authorisation and discipline on the MOPH documentation template, a Qatari local agent with a strong MOPH and HMC track record, and a written commercial framework that aligns on bilingual labelling, halal evidence, Special Use timing and pricing. Where those three are aligned, supply into Qatar from the UK is fast, predictable and operationally robust.